abstract |
The present invention provides a method for treating diseases susceptible to treatment with IFN-α, particularly chronic HCV infection, melanoma, renal cell carcinoma (RCC), or chronic myeloid leukemia (CML). Use of genetic markers on human chromosome 19 associated with beneficial responses to interferon alpha (IFN-α), and IFN-α pharmaceutical compositions and pharmaceutical products. [Selection figure] None |